Next Phase Newsletter

A firm is a single family office of Maryland and New Jersey-based family interests. While the firm is very flexible in terms of investment size they are generally looking to invest a minimum of $.5 million per round, depending upon size of round and estimated capital call. FoxHill prefers A round and later stage companies. Pre-A interest depends upon technology stage. Our preferred geography is North America and Europe.

The firm is looking for breakthrough technologies with a strong social ethos in the Therapeutics, Medical Devices, and Diagnostics Sectors that address underserved medical needs or provide innovative and disruptive approaches to common medical procedures and treatments. The firm invests on an opportunistic basis in areas of intersecting technologies, such as nucleic acid-based drugs and delivery, regenerative medicine and cell-based therapeutics and other immune-directed therapies. The firm generally will not consider single target small molecules, biosimilars or other technologies for which there is already multiple therapeutic options. The firm is looking for niche disease areas where disruptive therapeutics have the potential to be truly disease-modifying, not just provide symptomatic relief or palliative care. The firm typically is interested in preclinical stage assets that have well-developed animal model dossiers to Phase II or early Phase III stage assets. The firm’s investment mandate particularly focuses on “smart” clinical trial formats such as adaptive trials and Master Protocol trials for capital efficiency. For devices, the firm is looking for devices that address and perhaps substitute for a pharmacologic in a given therapeutic market, such as deep brain stimulation technologies and orthopedics. The firm is generally not interested in cardiovascular disease or diabetes.

The firm is currently reviewing co-investment opportunities in private companies and on an opportunistic basis, considering investment in micro-and small-cap public companies as a direct investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com

A Venture Capital firm was founded in 2020 and is located in Plano, Texas. The firm is different from a traditional VC in that it focuses on investing, building and scaling life science start ups. The goal is to co-innovate and grow with the startups they invest in. The firm has a fund that is financed by 35 angels groups as well as a hedge fund. Investments are mainly in the form of equity and in-licensing, but the firm is flexible on a case-by-case basis with convertible notes. The firm has 7 life science companies in their portfolio to date. The firm’s main focus is biotech, medtech, and AI and machine learning technologies. The firm’s goal is to build innovations in hospitals that transform the lives of patients and make doctors jobs easier. The firm focuses on Pre-Seed, Seed and Series A financing rounds. The firm is open to global opportunities.

The firm focuses on AI, machine learning, and other biotech/medtech technologies, and within those domains, are open to all 4 main sectors. The firm looks for technologies in: consumer health, connected health practices, patient engagement related arenas, telehealth, distal therapeutics, and consumer health solutions and services. The firm doesn’t focus on traditional medical devices, but is looking to invest in “smart” medical devices that support connected health practices. The firm is open to most indications, especially oncology, women’s health, mental health, respiratory, cardiology, and pediatrics. The firm is not interested in drugs therapeutics or immunology with the exception of mRNA vaccines. The firm invests in pre-clinical companies.

The firm is looking for a team that they can work and co-innovate with and do channel partnering with to scale their businesses. For this firm, the concept or idea is the most important part and they are looking for more than what companies built today, they look for the future impact. Interested companies should have management teams that are in alignment with the firm’s values and that their end outcome is patient success. The firm can lead or co-invest on a case by case basis and will seek board seat representation on a case by case basis as well.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A newly established venture capital firm based in the USA has just successfully closed the first round of their fund ($20M target), and made its first investment. The firm invests globally in medically related early-stage companies. Initial size of investment ranges from $250 – 500K. While the firm is focused on USA-based companies, the firm is open to considering companies across the globe.

The firm invests in medtech and digital health companies. While the founder has decades of experience as an oculofacial plastic surgeon, the firm is generally opportunistic and will consider any promising technologies that address unmet medical need. The firm has looked at AI companies, digital health/software companies implementable in medical practices, etc. In terms of stage of development, the firm is open to investing as early as pre-prototype, given that the company has properly researched the idea behind their technology.

The firm has no specific company or management team requirements, and is open to acting as either a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com

The firm is a global chemical company founded in 1935. A subsidiary was initially established as the firm’s first U.S. representative office in NY in 1964 and has grown to become the corporation’s main sales, marketing, and business development center in North America. In addition to a variety of other markets, the firm serves the chemical, petrochemical and bioscience markets. The firm has recently started a corporate venture initiative with a $300M budget to make strategic investments into both pre and post-commercial companies. The group is flexible in terms of structuring investments and may employ equity investments, M&A and licensing agreements. The firm targets investment sizes from $100k – $5M for early stage companies and $10M-$50M for commercial-stage companies.

In terms of the healthcare and life science sectors, the firm is most interested in companies working in diagnostics and research tools. The firm is particularly interested in clinical diagnostics including IVDs and next generation platforms (NGS, liquid biopsy, LC-MS, point-of-care testing, digital PCR), separation media and connected devices and wearable medical sensors. The group is also interested in advanced materials including materials for secondary batteries, thin-film for electronic devices, separation (inorganic/organic/polymers) and composites. The firm is agnostic to indication area, but has a particular interest in cancer, metabolic (including diabetes) and kidney disorders as well as reproductive health.

The firm has no strict company or management team requirements and invest in both early and later stage opportunities. Board observer status is required along with an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is the corporate venture arm of an insurance company and is based in the Midwest. The firm was founded in 2016 and since then has made 30 investments. One of the firm’s main focus areas is in the longevity space as well as long term care. Within this space, the firm is open to all four sectors. The firm currently has a $350M fund and focuses mainly on Series A and B rounds in the form of equity, but will occasionally look at Seed rounds or late-stage rounds as well on a case by case basis. The firm is open to global opportunities, with a focus in US and Israeli markets.

The firm focuses on longevity investments and are open to all four life science sectors within that space. The firm looks for companies that have healthcare platforms that relate to monitoring and managing chronic conditions, as well as long term care and care coordination platforms. The firm is also interested in fintech companies focused on the retirement space as well as health data companies where the firm can find sources of data for life insurance and underwriting services. The firm will invest in all 3 classes of medical devices. The firm is not interested in biomedical companies and they do not invest in pre-clinical or pre-prototype companies.

The firm is open to all types of management teams from any type of background. The firm does not lead investments and prefers to co-invest

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The venture fund is an early stage investor in emerging life science technologies that was founded in 2003 and is based in Washington, with additional offices in New York City and San Diego. The firm closed its fourth fund in 2015 at $62.8 million. The firm seeks to invest in promising early-stage assets, create a company around each asset and then directly manage the startup. The firm’s investment sizes vary from $1-40 million. Investments are made at the seed stage or in Series A venture rounds; the firm prefers to be the first institutional investor. The firm has invested in assets sourced throughout the USA and has evaluated investment opportunities globally.

The firm primarily invests in therapeutics-focused opportunities. The firm is technologically agnostic and is open to any indication area, with a particular interest in CNS, digital health, oncology and immunology. The firm is interested in preclinical-stage assets and will consider investing in assets as early as the discovery stage.

The firm is open to working with both academic projects and entrepreneurs, and also deprioritized pharma assets. The firm generally does not make new investments into companies any later than the Series A stage. The firm supplies management and technical expertise to develop an asset if the company does not have a full management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Founded in 2019, a China-based firm sponsored by the local municipal government manages 2 funds that associated with their local incubator: one USD fund of $100MM and one RMB fund of $1,000MM, and is open to global in-licensing opportunities.

The firm focuses on Class II and Class III medical devices at the development stage, especially prototype-ready projects. The firm pays special attention to companies that are developing projects related to stroke, cardiovascular disease, eye disease, and medical robots. Currently, the firm is not interested in the IVD sector.

The firm prefers companies with a Chinese angle and are open to discussing China rights.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.